Digital Proficiency Testing for interpretation of slide-based biomarkers in lung and breast cancer
The following modules are now open:
IHC HER2 (4B5) with focus on 0 and 1+ scores
HER2 Dual ISH
IHC PD-L1 (SP142) in Triple Negative Breast Cancer
Non-Small Cell Lung Cancer:
IHC ALK (D5F3)
IHC PD-L1 (SP263)
IHC PD-L1 (SP142)
IHC ROS1 (SP384)
All modules will close at Midnight UK time (GMT +1) on 20th September 2023
Once you have registered you will receive joining details and an email whenever we open new rounds for your preferred biomarker indication(s).
If you have previously registered, and agreed to receive emails from us, we will notify you whenever we open new rounds of interest.
Each of our modules contain a maximum of 6 cases and we follow up with live, interactive sessions using a virtual multi-header microscope. These sessions include a short presentation on current developments in either breast or lung cancer biomarkers.
For any assistance please contact firstname.lastname@example.org